FountainRx Specialty Pharmacy Selected by Dexcel Pharma to Distribute Vigabatrin

FountainRx Specialty Pharmacy, a national, independently owned provider of specialty pharmacy and infusion services, recently announced that Dexcel Pharma USA has selected it as a Risk Evaluation and Mitigation Strategy (REMS) certified distribution partner for vigabatrin tablets USP (500 mg).

Vigabatrin is used to treat and manage infantile spasms in infants 1 month to 2 years old for whom the potential benefits outweigh the potential risk of vision loss and refractory complex partial seizures in patients 2 years of age and older who have responded inadequately to several alternative treatments.

FountainRx delivers comprehensive specialty pharmacy services to patients using vigabatrin to ensure their treatment success.

The company works with patients through every step of the process to coordinate their care and monitor their progress, providing expert knowledge and a supportive environment for individualized solutions.

Dexcel Pharma is the largest private pharmaceutical company in Israel, commercializing an extensive portfolio of branded and generic drugs. The company’s state-of-the-art R&D and manufacturing facilities enable us to develop and manufacture high-quality products while maintaining long-term partnerships across the value chain.

FountainRx Specialty Pharmacy also recently announced that it is licensed in all 50 states for specialty pharmacy, having recently added Alabama and California. The company can serve patients nationwide, providing effective and targeted medication solutions for those with chronic and rare health conditions.

In 2024, FountainRx expanded its technology and services through strategic partnerships with ScriptMed, Inovalon’s pharmacy management software, and Pleio, Inc. to provide a concierge-level experience to patients.

These partnerships will help the company to provide a superior experience as well as personalized, cost-effective care for patients as it continues to grow.